LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Akcijų sąrašas・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Uždarymo kaina

4.29 -4.24

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.29

Max

4.33

Pagrindiniai rodikliai
By Trading Economics
Pajamos	4M -3.8M
Pardavimai	522K 1.1M
Pelnas, tenkantis vienai akcijai	-0.014
Pelno marža	-357.374
Darbuotojai	44
EBITDA	-1.1M -8.8M

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-13

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	12M 851M
Ankstesnė atidarymo kaina	8.53
Ankstesnė uždarymo kaina	4.29

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

3.255 / 3.365 Palaikymas ir pasipriešinimas

Arbutus Biopharma Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-27 17:33; UTC

Svarbiausios naujienos

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

2026-03-27 17:00; UTC

Svarbiausios naujienos

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

2026-03-27 16:03; UTC

Svarbiausios naujienos

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

2026-03-29 23:47; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Falls Amid Rising Inflation Fears -- Market Talk

2026-03-29 23:46; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

2026-03-29 23:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

2026-03-29 23:23; UTC

Rinkos pokalbiai

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

2026-03-29 22:34; UTC

Rinkos pokalbiai

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

2026-03-29 22:09; UTC

Rinkos pokalbiai

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

2026-03-29 21:06; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

2026-03-29 21:03; UTC

Rinkos pokalbiai

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

2026-03-29 21:01; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

2026-03-29 09:30; UTC

Įsigijimai, susijungimai, perėmimai

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

2026-03-28 08:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-27 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-27 19:16; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

2026-03-27 19:07; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

2026-03-27 19:04; UTC

Rinkos pokalbiai

Gold Rises But Can't Finish the Week Positive -- Market Talk

2026-03-27 19:03; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 19:02; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

2026-03-27 18:12; UTC

Rinkos pokalbiai

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

2026-03-27 17:36; UTC

Svarbiausios naujienos

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

2026-03-27 17:34; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

2026-03-27 17:29; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

2026-03-27 16:38; UTC

Rinkos pokalbiai

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

2026-03-27 16:32; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

2026-03-27 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-27 15:43; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

2026-03-27 15:25; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 15:25; UTC

Rinkos pokalbiai

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Akcijų palyginimas

Kainos pokytis

Arbutus Biopharma Corp Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Arbutus Biopharma Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.255 / 3.365Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.